EPHA2 and breast cancer: Ogawa et al. used both xenograft models and human tissue samples to demonstrate its upregulation, together with its ligand ephrin-A1, in the vasculature of mammary tumors, proposing EPHA2 as a possible anti-angiogenic therapeutic target [24].